MedTrace Logo

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

NCT01716806 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2024-06-11

Study results available
· View outcomes & findings →

Summary

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.

Conditions

  • Hodgkin Disease
  • Peripheral T Cell Lymphoma

Interventions

DRUG

brentuximab vedotin

1.8 mg/kg every 3 weeks by IV infusion

DRUG

bendamustine

70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle

DRUG

dacarbazine

375 mg/m\^2 every 3 weeks by IV infusion

DRUG

nivolumab

3 mg/kg every 3 weeks by IV infusion

Sponsors & Collaborators

Principal Investigators

  • Robert Sims, MD · Seagen Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2023-04-07
Completion
2023-09-12

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01716806 on ClinicalTrials.gov